Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTHOS: EC-MPS and Valsartan in Kidney Transplant
NCT00308425Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of valsartan in Transplant Nephropathy, sponsored by Novartis. Primary endpoint: 12-month rate of success in preventing relapse of nephropathy. Started Oct 2002; status: completed.
02
Drugs
valsartan
03
Conditions
Transplant Nephropathy
Beyond the preview
Go deeper on NCT00308425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308425.